Last Updated: August 3, 2026

PAROXETINE MESYLATE Drug Patent Profile

✉ Email this page to a colleague

When do Paroxetine Mesylate patents expire, and when can generic versions of Paroxetine Mesylate launch?

Paroxetine Mesylate is a drug marketed by Actavis Labs Fl Inc and Prinston Inc and is included in two NDAs.

The generic ingredient in PAROXETINE MESYLATE is paroxetine mesylate. There are thirty drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the paroxetine mesylate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Paroxetine Mesylate

A generic version of PAROXETINE MESYLATE was approved as paroxetine mesylate by ACTAVIS LABS FL INC on June 20^th, 2017.

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for PAROXETINE MESYLATE?
What are the global sales for PAROXETINE MESYLATE?
What is Average Wholesale Price for PAROXETINE MESYLATE?

Summary for PAROXETINE MESYLATE

US Patents:	0
Applicants:	2
NDAs:	2
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for PAROXETINE MESYLATE

Paragraph IV (Patent) Challenges for PAROXETINE MESYLATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
BRISDELLE	Capsules	paroxetine mesylate	7.5 mg	204516	1	2014-04-07

US Patents and Regulatory Information for PAROXETINE MESYLATE

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Actavis Labs Fl Inc	PAROXETINE MESYLATE	paroxetine mesylate	CAPSULE;ORAL	207139-001	Jun 20, 2017	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Prinston Inc	PAROXETINE MESYLATE	paroxetine mesylate	CAPSULE;ORAL	207188-001	Aug 18, 2017	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.